| Popis: |
Introduction The appointment of a DPP 4 inhibitor in patients with СAD and DM 2 with moderate ejection fraction (HFmrEF) continues to be studied. Purpose Analysis of glycemic parameters in patients with CAD, with DM 2, depending on the phenotype of HF when taking sitagliptin/metformin (S/M). Methods We examined 50 patients with CAD with DM 2 at the age of 62.8±1.29 years. Determined fasting glycemia (FG), postprandial (PPG), HbA1c, Echocardiography. Compiled by groups with HFpEF n-33, HFmrEF n-17. Treatment regimen: basic therapy for CAD, S/M). Follow-up for 48 weeks. Results In patients with HFmrEF, we have differences vs the group with HFpEF in the incidence of PCI in history - 58.8 vs 24.2% (χ2=5.752; P=0.017); eGFR Conclusion Conclusion. With HFmrEF, the incidence of PCI, eGFR |
Full Text from ScienceDirect